ENCLAI Daily · Article of the day 19 Nov 2026 · ENCLAI Editorial

Umbrella review finds no tuberculosis biomarker meets WHO accuracy targets

NEW MEDICAL STUDY · META-ANALYSIS · 19 NOVEMBER 2026Umbrella review finds no tuberculosisbiomarker meets WHO accuracy targetsPubMed 43044621Systematic reviewStudy typeLancet Microbejournal17 Nov 2026published**An umbrella review of 46 systematic reviews found that no hostor pathogen-derived biomarker consistently met World HealthOrganization target product profile accuracy thresholds fordetecting, predicting progression of, or monitoring tuberculosistreatment.What the study found1The analysis included 46 reviews: 40 on detection, seven onprogression, and six on treatment monitoring, with some addressingmultiple use cases.2For detection, evidence was strongest for host proteins, hosttranscriptomics, and pathogen antigens.3For progression, evidence was strongest for host transcriptomics,particularly for short-term risk prediction.Who it applies toThe authors searched MEDLINE, Web ofScience, Global Index Medicus, and theCochrane Library from inception toSeptember 1, 2025.What it does not establishThe authors note that most primarystudies were at high risk of selectionbias and accuracy estimates variedwidely.The authors' conclusion“**An umbrella review of 46 systematic reviews found that no host orpathogen-derived biomarker consistently met World Health Organizationtarget product profile accuracy thresholds for detecting, predictingprogression of, or monitoring tuberculosis treatment.”Summary of the published abstract, not medical advice. Read the paper before acting on it.Source: PubMed 43044621 · enclai.net/newsVerify every figure against the source before use; ENCLAI does not guarantee accuracy orcompleteness.
  1. **An umbrella review of 46 systematic reviews found that no host or pathogen-derived biomarker consistently met World Health Organization target product profile accuracy thresholds for detecting, predicting progression of, or monitoring tuberculosis treatment.
  2. The analysis included 46 reviews: 40 on detection, seven on progression, and six on treatment monitoring, with some addressing multiple use cases.
  3. For detection, evidence was strongest for host proteins, host transcriptomics, and pathogen antigens.
  4. For progression, evidence was strongest for host transcriptomics, particularly for short-term risk prediction.
Customise it in Visual Studio
Infographic — study at a glance
What the authors report
Evidence and source
Infographic — study at a glance

The publication

**An umbrella review of 46 systematic reviews found that no host or pathogen-derived biomarker consistently met World Health Organization target product profile accuracy thresholds for detecting, predicting progression of, or monitoring tuberculosis treatment. While evidence was strongest for host proteins and transcriptomics in detection and short-term risk prediction, most primary studies carried a high risk of selection bias.**

Who the findings apply to

The authors searched MEDLINE, Web of Science, Global Index Medicus, and the Cochrane Library from inception to September 1, 2025. They included systematic reviews on host-derived and pathogen-derived biomarkers for three use cases: detection of disease, prediction of progression to disease, and treatment monitoring and optimization. Reviews confined to WHO-endorsed tests for approved use cases were excluded.

Why this matters

The review addresses fragmented evidence regarding numerous described tuberculosis biomarkers by synthesizing findings across nine biomarker classes. It aims to determine which markers have potential to improve individual and public health outcomes for disease detection, progression prediction, and treatment optimization.

What the study found

The analysis included 46 reviews: 40 on detection, seven on progression, and six on treatment monitoring, with some addressing multiple use cases. For detection, evidence was strongest for host proteins, host transcriptomics, and pathogen antigens. For progression, evidence was strongest for host transcriptomics, particularly for short-term risk prediction. Evidence for predicting clinical outcomes in treatment monitoring was scarce.

Across all use cases, no biomarkers consistently met WHO target product profile accuracy thresholds. Most primary studies were at high risk of selection bias, and accuracy estimates varied widely.

What the result does not establish

The authors note that most primary studies were at high risk of selection bias and accuracy estimates varied widely. They conclude that prospective head-to-head studies in representative populations are needed to determine which biomarkers have potential to improve individual and public health outcomes.

The review excluded reviews confined to WHO-endorsed tests for approved use cases, focusing instead on emerging or non-standardized markers.

Authors’ conclusion

“Most primary studies were at high risk of selection bias, and accuracy estimates varied widely. Prospective head-to-head studies in representative populations are needed to determine which biomarkers have potential to improve individual and public health outcomes.”

Study and sources

Biomarkers for tuberculosis detection, progression, and treatment optimisation: an umbrella review of systematic reviews

Systematic review / meta-analysis · Lancet Microbe · 2026-11-17

Sources and limitations

Share this briefing
ENCLAI tracks outbreaks like this live, from official sources worldwide. Start 7-day free trial  ·  Request a demo →

Follow ENCLAI News

Get new briefings in your news reader. No ENCLAI account needed.

The daily disease brief

One email a day: what changed in official disease reporting worldwide, with the source named for every number. Reported facts only — no forecasts and no interpretation.

Double opt-in — we send a confirmation link and nothing else until you click it. One-click unsubscribe on every email. See our privacy notice.